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The oncogene-induced senescence is emerging as a potent tumor suppressor mechanism
and as a possible therapeutic target. Macroautophagy is intimately linked to the senescence
condition setup, although its role has not been elucidated yet. Here, we discuss up-to-date
concepts of senescence-related macroautophagy and evaluate the current trend of this
growing research field, which has relevance in future perspectives toward therapeutic
options against cancer.
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INTRODUCTION
Macroautophagy is a catabolic process for the recycling and degra-
dation of cellular constituents (1–3). The implication in several
physiological and pathological processes, as well as in basic cellular
mechanisms, has made macroautophagy one of the hot research
topics of the last decade. The increased interest in macroautophagy
has led to a deeper understanding of its molecular mechanisms,
unmasking it as a process with unthinkable roles. Macroautophagy
sequesters and degrades portions of cytoplasm including entire
organelles; this is termed bulk macroautophagy (2–4). In this way,
macroautophagy is an effector process of nutrient states sensing
factors, principally mTOR (mammalian Target Of Rapamycin)
and AMPK (AMP-activated Protein Kinase) (5). The mTORC1
(mTOR Complex-1) is composed by RAPTOR and DEPTOR, two
negative regulators, mLST8, a positive regulator, and PRAS40 (6).
With the Ser/Thr protein kinase activity of mTOR, the mTORC1
is a key integrator of the nutrient status and nutrients availability,
growth factors, and stress signals (6). In amino acid starvation,
mTORC1 is inactivated and distributed dispersed into the cyto-
plasm. Upon amino acid stimulation, mTORC1 is redistributed
mainly to lysosomal membranes where, in response to amino
acids, RAG GTPases activate the complex (6). Finally, the plenty
nutrient state activates the mTORC1, which in turn induces cell
growth and protein synthesis, and inhibits catabolic processes such
as macroautophagy (5, 6).
The first link between the nutritional cell condition and
macroautophagy is the protein kinase Ulk1 (Unc-51 like kinase-1),
or its homolog Ulk2 (5). Ulk1 forms a complex with Atg13 and
FIP200 that enhances the activity of the protein kinase Ulk1
(5). Activated mTORC1 maintains Atg13 and Ulk1 in a hyper-
phosphorylated state, avoiding the triggering of the macroau-
tophagy. In starvation, the inactivation of mTORC1 leads to the
hypophosphorylation of these proteins, releasing and activating
the Ulk1 complex. Although the substrate of Ulk1 is so far
unknown, the kinase activity of this complex is able to initiate
the macroautophagy cascade (5).
Structurally, macroautophagy starts with the omegasome, which
is a structure that sprouts from the ER membrane, and grows by
lipids and several macroautophagy proteins (2, 3). This budding-
like process gives initiation to the phagophore, a tiny vesicle pre-
cursor of the isolation membrane that is formed by the growing of
the phagophore with more lipids and autophagy-related proteins
(ATG proteins) (7). This bigger membrane eventually engulfs the
cargo, forming a double membrane vesicle termed the autophago-
some. The outer membrane of the autophagosome fuses with
lysosomes for the delivery of its inner vesicle and cargo into a
degradative organelle (the autophagolysosome) (7) (Figure 1A).
The deeper insight into these phenomena has revealed more
specialized and highly controlled forms of macroautophagy.
Although all types of macroautophagy may share the same core
molecular machinery involved in the autophagosome forma-
tion, today we recognize conceptually and mechanistically several
forms of selective macroautophagy such as mitophagy, pexophagy,
ribophagy, lipophagy, and zymophagy (8, 9). Furthermore, the
macroautophagy field has also expanded its implication in phys-
iological and pathological processes, such as life span, starva-
tion, embryogenesis, cancer, degenerative diseases, Crohn’s disease,
pancreatitis, and host defense.
MACROAUTOPHAGY IN CANCER
The role of macroautophagy in cancer is quite conflictive and
confusing (10). In mammals, it has been linked to tumor devel-
opment, since one of the most important macroautophagy-
related molecules, Beclin 1 (a Bcl2-interacting protein), is a
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FIGURE 1 | (A) General scheme of macroautophagy process. The initial
isolation membrane is grown by lipids and macroautophagy-related proteins
in order to engulf the cargo target. Then, the fusion of the isolation
membrane edges forms a double membrane vesicle, termed
autophagosome. The autophagosome eventually fuses with lysosome,
resulting in the autophagolysosome. Finally, it is in the autophagolysosome
where cargo and autophagosome inner membrane are degraded by the
lysosomal enzymes. (B) Normal cell after oncogene activation. After
oncogene activation, cells have at least two possible fates. One of them is
an oncogene-driven transformation where senescence must be bypassed,
and macroautophagy inhibition could contribute to this bypassing. The other
option is to enter in an oncogene-induced senescence with a permanent
cell cycle arrest. During oncogene-induced senescence, three phases are
observed: the mitotic phase, with high proliferation rate; the transition
phase, with the possible participation of Ulk3 in the macroautophagy
triggering and apparition of TASCC (see text); finally, the senescence phase
with the definitely senescence phenotype established.
haploinsufficient tumor suppressor gene (11, 12). Indeed, in Beclin
1+/− transgenic mice, that display reduced macroautophagy
levels, a significant increase of spontaneous tumor incidence
is observed (13). Several reports present macroautophagy and
macroautophagic cell death as anti-tumoral responses. On the
other hand, macroautophagy is related to chemotherapeutics resis-
tance (14, 15) and to the enhancement of cancer-cell metabolism
during hypoxic and nutrient-deficient environments (16).
ONCOGENE-INDUCED SENESCENCE
The term cellular senescence is used to describe a deep and irre-
versible arrest status of the cell cycle. In this process, cells suffer
a radical transformation with a strong repression of proliferation
genes that eventually cause an increase in heterochromatin areas
into the nucleus, loss of response to growth factors, and also a
deep modification in cell metabolism and morphology including
an expanded and flattened cytoplasm shape, and increase of focal
adhesions among others (17). Lysosomal enzyme β-galactosidase
activity at pH 6.0 is the hallmark and the most spread assay
for senescence determination, the so-called senescence-associated
β-galactosidase (SA-βGal). In spite of this, the SA-βGal assay is
not fully specific for senescence, since it could be positive also
in other cellular conditions (18). Consequently, a conjunction
of markers should be used to evaluate senescence more accu-
rately. Among such markers are: the cell morphology, the presence
of SAHFs (Senescence-Associated Heterochromatic Focis), DNA
damage response (DDR) markers (i.e., γ-H2AX, CHK2,) and the
evaluation of p53, p16INK4a, and p21CIP1.
Curiously, the senescence is a common output response to
different cellular stressors. One of them is shortened telomeres
caused by the successive DNA replications. This type of senes-
cence is termed replicative senescence (sometimes abbreviated as
RS), and was first described by Hayflick in 1961 (19), who demon-
strated that cells possess a limited number of replications by means
of successive passage of human diploid fibroblasts. In this set-
ting, the unprotected telomeres are interpreted as double strand
breaks of DNA and trigger the cellular DDR, which eventually
activates the cellular arrest mechanisms (20). The final effector
pathways are through the p53/p21CIP1 and p16INK4a axes, leading
to the hypophosphorylated form of Rb, which in turn represses the
activity of cell cycle progression-related transcription factors (20).
Furthermore, the agents or events that lead to DNA damage, such
as UV light, chemotherapeutics, and ROS, are capable of trigger-
ing a premature senescence in the cell (21, 22). This last event, is
commonly entitled as stress-induced premature senescence (some-
times abbreviated as SIPS), and also activates the DDR system in
order to arrest the cell cycle in a telomere-independent fashion.
Finally, the senescence program can be additionally triggered by
the activation of an oncogene, termed oncogene-induced senescence
(sometimes abbreviated as OIS) (21, 22). The oncogene-induced
senescence is also independent of telomeres and can be medi-
ated by the DDR program. It could be possible that the initial
high replication rates, induced by oncogene activation, results in
DNA damage, a process where the ROS generation could also be
implicated (21, 22). Nevertheless, the oncogene-induced senes-
cence is also able to trigger senescence independently of DDR
activation, by induction of the p53/p21CIP1 or p16INK4a path-
ways, but the mechanism is not fully understood (20). Finally,
these differences are clearly appreciated in recent data that com-
pare gene expression levels between the replicative senescence and
the oncogene-induced senescence. Although the final consequence
is the same, meaning the senescence phenotype, there are deep
differences in the genetic programs implicated in both cases (23).
The first description by Hayflick (19) promoted the idea that
senescence probably was just an in vitro artifact. However, as more
data are being obtained, senescence is recognized as a true cellu-
lar “aging ” program (17, 24). Concerning the impact of cellular
senescence to the whole organism, Martin et al. (25) and Gold-
stein et al. (26) found an impairment in the replicative capacity
of fibroblast from accelerated aging syndromes and age-related
human diseases. However, there is not enough evidence to relate
the duplication capacity of fibroblasts with the lifespan of the
organisms (27). Recent interesting findings in the field show that
senescence is a key cellular pathway (28), which may function
as an alternative mechanism to apoptosis in response to certain
stressors. Thereby, the oncogene-induced senescence appears to
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play a role as a tumor suppressor mechanism against cellular trans-
formation (29–32). The oncogene-induced senescence has been
reported in several murine (29) and human (29) tumors; and is
believed to be one of the first cellular barriers against transfor-
mation (30, 33). One excellent example is the results reported by
Guerra et al. (33) using a murine model of pancreatic carcinogen-
esis. The transgenic expression of the oncogenic Kras is only able
to induce low grade pre-cancerous structures into the pancreatic
tissue. These structures are highly positive for different senescence
markers and only after the induction of pancreatitis, senescence
can be overcome and the model progresses toward tumor devel-
opment (33). Upon oncogene activation, cells have three principal
outcomes: to proliferate; to trigger an oncogene-induced apopto-
sis; or to enter in an oncogene-induced senescence process (29,
30). One example is the K562 leukemia cells in which the ima-
tinib treatment induces massive apoptosis with low percentage of
cells entering in senescence; but this percentage of senescent cells
is highly increased when apoptosis is inhibited (34). Therefore,
one of the events that cells can induce against oncogene activation
is the senescence, which apparently is triggered by the oncogene
itself. This senescence induction by oncogene activation and the
requirement to bypass the tumor suppressive process in order to
transform cells was clearly demonstrated by Pérez-Mancera and
Tuveson in 2006 (35). They infected mouse embryonic fibroblasts
(MEFs) with a retrovirus carrying the oncogenic Ras, inducing a
supraphysiological oncogene expression (35). In that experiment,
the logical expectation is MEFs transformation, but instead of
that, MEFs surprisingly entered in an early senescence process
(35). More interestingly, when they activated a pre-existing LSL-
KrasG12D allele by a Cre recombinase virus, they obtained physio-
logical KrasG12D expression levels and a partial transformation was
reached (35). All these data suggest that oncogene-induced senes-
cence is a kind of failsafe mechanism. For example, cells respond
to growth factors with proliferation, but when things go out of
control, senescence appears into the game.
Despite the differences among cell types, a sequence of steps
is observed during the establishment of the oncogene-induced
senescence (27). This process consists in an initial response to the
oncogene activation, which leads to hyperproliferation, known
as mitotic phase. Then a transition phase, where the prolifera-
tion slows down and senescence characteristics start to be evident.
Finally, a senescence phase, where the process is widely established
(Figure 1B). Although there was significant progress in the past
years, the complete details about the oncogene-induced senescence
mechanisms remain to be elucidated.
MACROAUTOPHAGY AS SENESCENCE EFFECTOR
The pioneering works by Bergamini et al. (36, 37), early sug-
gested a relationship between macroautophagy and aging. Follow-
ing publications strengthen those data, linking macroautophagy
to senescence-related events. Furthermore, recent works strongly
support the key role of macroautophagy in the oncogene-induced
senescence process. During senescence, there is a gradual increase
in Bag3/Bag1 ratio inducing a cellular switch from proteasome to
macroautophagy for polyubiquitinated proteins degradation (38).
This phenomenon is also observed in tissue aging (38). In addition,
it was suggested that the macroautophagy pathway during the
oncogene-induced senescence has the ability to process chromatin,
contributing to stability of senescence and tumor suppression (39).
Macroautophagy was found several times during senescence
in the transition phase (40), but it was not until the work of
Young et al. (41) that macroautophagy was described as a senes-
cence effector. They observed an increased macroautophagy level
in IMR90 cells entering in senescence by HrasV12 retroviral trans-
duction, which is not observed in quiescent cells (41). They
documented that senescence led to a high coupling synthesis-
degradation with an apparently paradoxical situation, where
the same cell presents high macroautophagy activity with the
autophagy inhibitor, mTOR, activated at the same time (41). This
situation was explained by the outstanding publication by Narita
et al. (42), with the introduction of the TOR-autophagy spatial cou-
pling compartment (TASCC) concept. They described an amazing
cytoplasmic sub-compartmentalization, the TASCC, where cell lit-
erally hide mTORC1 from macroautophagy machinery in order to
avoid its inactivation (42). In TASCC, mTOR is closely associated
with lysosomes/autolysosomes, fueled by a constant macroau-
tophagy flow outside this area (42). In this way, the amino acids
released by lysosomal degradation maintain mTOR activation,
thereby sustaining a high protein synthesis level (42). Moreover,
this synthesis–degradation coupling through the TASCC seems to
be important in the physiology of some specialized cells, such as
the kidneys’ podocytes that have the constitutive need to phago-
cyte and degrade the glomerulus basal membrane and at the
same time maintain protein synthesis (42, 43). This opens the
possibility that TASCC can additionally play other physiological
functions. For example, recently we described the important role
of zymophagy (selective macroautophagy of activated zymogen
granules) to prevent intracellular activation of zymogen gran-
ules in pancreatic acinar cells (8). These cells have a metabolism
almost completely dedicated to protein synthesis to accomplish
their function (44). Therefore, we can hypothesize that the TASCC
strategy can allow the zymogen synthesis and at the same time the
prophylactic basal zymophagy activity. Nevertheless, whether the
TASCC has always the same composition and function remains
unknown.
ROLE OF MACROAUTOPHAGY IN SENESCENCE
It is interesting that macroautophagy seems to be very important to
the senescence process, but its role seems to depend on the cellular
context and the experimental settings. In normal cells, the 3-
methyladenine-mediated inhibition of macroautophagy produces
a significant attenuation in the premature senescence developed
by HUVEC cells exposed to glycated collagen I (45). In this work,
it is also suggested that, at least in this case, macroautophagy is
triggered by the lysosomal membrane permeabilization as cellular
stress response, which in turn leads to a senescence phenotype
(45). Lysosomes are the final destination of autophagosomes;
hence, a dysfunction of these organelles impairs the autolyso-
some formation and consequently the autophagic flow. In this
way, Patschan et al. (45) observed that the lysosomal membrane
permeabilization induces macroautophagy and triggers a stress-
induced premature senescence, which is reversible by autophagy
inhibition. Altogether, these data reveal a profound relationship
between the macroautophagy processes and senescence.
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In immortalized cells, Young et al. (41) showed that the ade-
noviral oncoprotein E1A expression suppresses the Ras-induced
senescence and significantly reduces the macroautophagy and
protein degradation. These data suggest that macroautophagy
contributes to oncogene-induced senescence. Singh et al. (46) fur-
ther support this concept by showing that chronic expression of a
proteolytic Cyclin E fragment induces autophagy and senescence.
Furthermore, senescence is prevented by macroautophagy inhibi-
tion and in turn, apoptosis is triggered (46). What is more, induced
senescence in that setting is Atg7-dependent (46). In the work of
Drullion et al. (34), commented above, a significant reduction of
SA-βGal positive cells was observed upon downregulation of Atg7
or Beclin 1. Very interestingly, is the fact that conversely to Atg7,
the depletion of Atg5 induces an increased number of SA-βGal
positive cells (34).
In the case of transformed cells, the retrovirus-mediated HrasV12
transduction in diverse human diploid fibroblasts cells (IMR90, BJ,
or embryonic skin fibroblasts) produces an increase in macroau-
tophagy levels and a subsequent senescence (41). In those experi-
ments, the shRNA-mediated depletion of Atg5 or Atg7 attenuates
the Ras-activated autophagy and delays the SA-βGal in IMR90
cells. Moreover, in BJ cells, the downregulation of one or the
other autophagic-related proteins is enough to bypass senescence
(41). Dissimilar results come from the work of Wang et al. (47).
They show that ASPP2 (apoptosis-stimulating of p53 protein 2),
through its Nt-domain, inhibits macroautophagy and in this fash-
ion induces oncogene-induced senescence in MEFs transduced
with the oncogenic HrasV12 (47). Furthermore, similar to the
results by Drullion et al. (34) about Atg5, Wang observed that
under Atg5 overexpression, cells are able to bypass the Ras-induced
senescence. On the contrary, the depletion of Atg5 or Atg3, under
the oncogenic Ras expression, condemns the cells to senescence
(47). Altogether, these data suggest that despite some discrepan-
cies, macroautophagy plays a key role in the establishment of the
senescence phenotype. What is more interesting is that according
to these findings, Atg5 and Atg7 might play opposite roles in senes-
cence. They are both very important molecules implicated in the
macroautophagy, but their antagonism in the senescence induc-
tion may suggest a finely tuning of the macroautophagy-associated
senescence. However, further work is needed to fully understand
this process.
Working with chemoresistant cells from tumor tissue, Nam
et al. (48, 49) observed that prolonged macroautophagy, due to
mTOR inhibition, triggers senescence (48, 49). In this case, the
mTOR inhibition seems to have key role. However, we have to
take into account that different to aforementioned data, cells are
already transformed. Of note, this is strengthened by xenograft
experiments, where the rapamycin (mTOR inhibitor) treatment
increases macroautophagy and SA-βGal positive staining, and
delays tumor growth (48, 49). Dissimilar results are also obtained
in iPSCs (induced pluripotent stem cells) with a senescence
dependent in mTOR activity (50). In this experimental model,
rapamycin treatment inhibits mTOR activity, and the consequent
induction of macroautophagy leads cells to prevent senescence
and promote reprograming (50). Here, again we have discrepan-
cies in the role of autophagy in senescence. Although they are
quite different in experimental situations, in both of them we
have a rapamycin treatment, which inhibit mTOR activity with
the consequent increase in macroautophagy activity. In this appar-
ently similar experimental context, the increased macroautophagy
is pro-senescence in the first experience and anti-senescence in
the second. Again, we could speculate about different macroau-
tophagy mechanisms such as different actions of Atg5 and Atg7,
commented before. However, we cannot discard that these dis-
crepancies could originate from differences in the intracellular
contexts.
Another possible explanation to the different roles of macroau-
tophagy in senescence could be that other/s pathway/s must
complement it, in order to reach one or another outcome. The
geroconversion is the term used to describe the conversion of
a cell from a quiescent state, a reversible arrest, to senescence,
which is an irreversible arrested state (51). Working with nor-
mal, transformed, and immortalized cells, Leontieva et al. (51)
demonstrated that cells in hypoxic conditions are more resistant to
senescence induction. The hypoxia increases macroautophagy and
inhibits mTOR activity, suppressing the geroconversion caused by
diverse stimuli (51). We have already mentioned the role of TASCC
during the oncogene-induced senescence, where the cytoplas-
mic sub-compartmentalization allows an operational macroau-
tophagy flux with an activated mTOR at the same time. Therefore,
we could speculate that macroautophagy is enough to reach a
cell’s state of quiescence, but the simultaneous mTOR activity
is needed as complement to arrive to the senescence pheno-
type. Additionally, also supporting this idea, Lerner et al. (52)
show that a chronic rapamycin treatment extends cell lifespan,
in a telomere-independent fashion of quiescent normal fibrob-
lasts. They described that chronic rapamycin-mediated inhibition
of mTOR, in those quiescent cells leads to an increase in mito-
chondrial mass and biogenesis, reduction of ROS (reactive oxygen
species) and macroautophagy induction, which in turn suppresses
senescence (52). Understanding the mechanisms behind these last
concepts is of fundamental importance for future approaches of
cancer therapeutics, more precisely in resolving the tumor cells
dormancy. Clinically, tumor dormancy explains the observations
that cancer patients can relapse years to decades after an appar-
ently successful treatment. In these situations, tumor cells remain
at the primary site or in distant metastases, which are causative
of major cancer-related deaths. In cell dormancy, the role of
oncogene pressure over the cell as well as the cellular microen-
vironment is of great importance (53). It has been demonstrated
that after some genetic and epigenetic modifications, tumor cells
can become oncogene addicted (53). In those cases, oncogene
inactivation can induce quiescence, differentiation, apoptosis, or
senescence (53). Moreover, unfavorable microenvironments can
also challenge the tumor cell into stressful conditions (54). In
those scenarios, autophagy plays a fundamental role in giving
a survival opportunity and maintaining a quiescent cell state
(54). All these data expose autophagy as double-bladed sword
since it can contribute to senescence, in an irreversible cell cycle
arrest that could be eliminated by the immune system, or it can
favor the cell toward quiescence in a dormancy state and future
relapse of disease. Different strategies in order to manipulate
macroautophagy to favor senescence over the quiescence must to
be evaluated.
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The description of specialized forms of macroautophagy in
eukaryotic cells, tempts us to hypothesize that there might be a
senescence-specific type of macroautophagy. The main contro-
versy about the role of macroautophagy in senescence comes from
the facts described above, where sometimes it is pro-senescent
and sometimes anti-senescent. We have already mentioned the
differences between Atg5 and Atg7 suggesting some unrelated
roles of these proteins in the senescence-related macroautophagy.
One small but interesting finding came from the work of Young
et al. (41), where canonicals Ulk1/2 protein kinases do not trig-
ger senescence-related macroautophagy. Instead, senescence is
triggered by Ulk3 (Figure 1B), which shares 31.6% of homol-
ogy with Ulk1/2 (5). Moreover, Ulk3 is able to colocalize with
Atg12-5-16 complex and its overexpression is sufficient to trigger
macroautophagy and senescence (41). These findings show that
senescence-related macroautophagy might have different mol-
ecular mechanisms. Taking into account that three homologs
of Ulk1/2 have been described, alternative mechanisms would
be possible (5). Further investigation is necessary to under-
stand the molecular relationships between macroautophagy and
senescence.
Finally, another aspect is the time of evaluation. In some cases,
macroautophagy is evaluated before and in others after the tran-
sition phase of senescence. In the first situation, macroautophagy
may contribute to senescence establishment, acting as a tumor
suppressor mechanism. However, once senescence is bypassed,
macroautophagy shows its dark side enhancing metabolic stress
resistance and even chemotherapeutic resistance of transformed
cells. Therefore, macroautophagy may have different functions
depending on the time of evaluation and more importantly, these
functions may involve different types of macroautophagy.
SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE
The senescence-associated secretory phenotype or SASP is a secre-
tory complex mix of proteins and molecules in which senescent
cells invest a lot of energy. It is composed, at least in part, by
pro-inflammatory cytokines, chemokines, and tissue remodeling
enzymes (55). It is believed that SASP induces some inflammatory
response and the clearance of senescent cells, although it could
also enhance malignancy (55, 56). In addition, SASP possesses a
paracrine effect, inducing and reinforcing senescence phenotype
in neighboring cells (56). Whether SASP is also able to induce
macroautophagy remains unclear.
On the other hand, macroautophagy actively participates in
SASP, since TASCC is fundamental to maintain the synthesis and
the release of these molecules in senescent cells (42, 57). In this
way, macroautophagy induction could favor the tissue response to
tumoral transformation. In recent years, the idea of a therapeutic-
induced senescence as a potential cancer treatment has gained
importance (30, 58, 59). However, that idea has a double edge,
since senescence induction could derive in tumor cell dormancy
and cancer relapse (60, 61).
CONCLUSION
In the recent years, a significant progress has been made in
the molecular mechanisms that link macroautophagy to senes-
cence, although, it seems to be the tip of the iceberg. The
future elucidation of the complete landscape surely will impact
strongly in our knowledge of cancer, its treatment, our vision of
cell’s tumor suppressive strategies, but it will also have impor-
tant implications in several physiological and pathophysiological
processes. Such is the case of TASSC description that seems to
have non-senescence-related physiological roles. These facts, in
addition to the control of oxidative stress by mitophagy or the
protective role of zymophagy in acinar cells, among other exam-
ples, strongly change our concept of macroautophagy from a
general catabolic process to a highly specific programed cellu-
lar process. This point of view shows macroautophagy plasticity
to make simple works such as the cytoplasm bulk degrada-
tion to highly regulated, and indeed compartmentalized in the
TASSC, senescence-related macroautophagy. Finally, the study of
senescence-related macroautophagy will reveal an unthinkable
plethora of new knowledge and, at the same time, will impact
in therapeutic strategies against complex human diseases.
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